QNCX
HEALTHCAREQuince Therapeutics Inc
$1.22-0.01 (-0.81%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving QNCX Today?
No stock-specific AI insight has been generated for QNCX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.80$45.50
$1.22
Fundamentals
Market Cap$20M
P/E Ratio—
EPS$-16.80
Dividend Yield—
Dividend / Share—
ROE-2.5%
Profit Margin—
Debt / Equity—
Trading
Volume726K
Avg Volume (10D)—
Shares Outstanding16.3M
QNCX News
20 articles- Quince Therapeutics Settles Approximately $16.4 Million of DebtYahoo Finance·Mar 30, 2026
- BC-Most Active StocksYahoo Finance·Mar 5, 2026
- Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic AlternativesYahoo Finance·Feb 9, 2026
- Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failureClinicaltrialsarena·Feb 2, 2026
- Spotify upgraded, Pinterest downgraded: Wall Street's top analyst callsYahoo Finance·Jan 30, 2026
- Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-TelangiectasiaYahoo Finance·Jan 29, 2026
- Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual MeetingYahoo Finance·Jan 28, 2026
- Quince Therapeutics price target raised to $5 from $4 at D. Boral CapitalYahoo Finance·Dec 16, 2025
- Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-TelangiectasiaYahoo Finance·Dec 15, 2025
- Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel DisordersYahoo Finance·Dec 10, 2025
- Quince Therapeutics to Participate at Investor Events in December 2025Yahoo Finance·Nov 24, 2025
- Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 12, 2025
- Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaYahoo Finance·Nov 10, 2025
- Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual MeetingYahoo Finance·Oct 9, 2025
- Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling StudyYahoo Finance·Sep 25, 2025
- Quince Therapeutics to Host Virtual Investor Day on October 2, 2025Yahoo Finance·Sep 11, 2025
- Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 2, 2025
- Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 11, 2025
- Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSPYahoo Finance·Aug 7, 2025
- Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaYahoo Finance·Jul 16, 2025
All 20 articles loaded
Price Data
Open$1.28
Previous Close$1.23
Day High$1.34
Day Low$1.26
52 Week High$45.50
52 Week Low$0.80
52-Week Range
$0.80$45.50
$1.22
Fundamentals
Market Cap$20M
P/E Ratio—
EPS$-16.80
Dividend Yield—
Dividend / Share—
ROE-2.5%
Profit Margin—
Debt / Equity—
Trading
Volume726K
Avg Volume (10D)—
Shares Outstanding16.3M
About Quince Therapeutics Inc
Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—